23基因表达特征用于中国长期队列髓母细胞瘤分子亚型分型的开发与验证
本研究基于三个已发表数据集(GSE21140、GSE37382、GSE37418)的460例样本建立髓母细胞瘤转录组数据库,识别出与分子亚型显著相关的23基因特征,分类准确率达95.2%。该特征在142例中国髓母细胞瘤患者长期队列中验证,将21例(15%)归为WNT型、41例(29%)为SHH型、16例(11%)为Group 3型、64例(45%)为Group 4型,各亚型5年总生存率分别为80%、62%、27%、47%(p < 0.0001)。23基因特征与Northcott的NanoString检测分型高度可比,一致率为96.4%。
要点
- 23基因特征在460例转录组数据库中对髓母细胞瘤分子亚型分类准确率达95.2%。
- 142例中国队列中WNT、SHH、Group 3、Group 4分别占15%、29%、11%、45%。
- 各亚型5年总生存率分别为80%、62%、27%、47%(p < 0.0001)。
核心结论
- 作者提出一种新型基因特征,能准确可靠地将FFPE髓母细胞瘤样本分配至分子亚型,可能作为临床分型的辅助工具。
- 作者认为未来需将该基因特征纳入前瞻性临床试验以进一步评估其临床价值。
研究设计与样本
- 研究建立来自三个已发表数据集(GSE21140、GSE37382、GSE37418)的460例髓母细胞瘤转录组数据库以识别23基因特征。
- 23基因特征在142例中国髓母细胞瘤患者长期队列中进一步验证。
主要发现
- 23基因特征与髓母细胞瘤亚型显著相关,分类准确率达95.2%。
- 142例中国队列中,23基因特征将21例(15%)归为WNT型、41例(29%)为SHH型、16例(11%)为Group 3型、64例(45%)为Group 4型。
- WNT、SHH、Group 3、Group 4型患者5年总生存率分别为80%、62%、27%、47%(p < 0.0001)。
- WNT、SHH、Group 3、Group 4型患者5年无进展生存率分别为80%、52%、27%、45%(p < 0.0001)。
- SHH/TP53突变型肿瘤较SHH/TP53野生型肿瘤及其他亚型预后更差;23基因特征与Northcott的NanoString检测分型一致率为96.4%。
关键数值与推荐
- 23基因特征分类准确率为95.2%。
- 与Northcott的NanoString检测分型一致率为96.4%。
- 各亚型5年总生存率:WNT型80%、SHH型62%、Group 3型27%、Group 4型47%(p < 0.0001)。
- 各亚型5年无进展生存率:WNT型80%、SHH型52%、Group 3型27%、Group 4型45%(p < 0.0001)。
临床怎么用
- 作者认为该23基因特征可能作为临床髓母细胞瘤分子分型的辅助工具。
- 作者认为未来需将该基因特征纳入前瞻性临床试验以进一步评估其临床价值。
局限性
- 作者认为未来需将该基因特征纳入前瞻性临床试验以进一步评估其临床价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Medulloblastoma is the most common childhood malignant brain tumor and is a leading cause of cancer-related death in children. Recent transcriptional studies have shown that medulloblastomas comprise at least four molecular subgroups, each with distinct demographics, genetics, and clinical outcomes. Medulloblastoma subtyping has become critical for subgroup-specific therapies. The use of gene expression assays to determine the molecular subgroup of clinical specimens is a long-awaited application of molecular biology for this pediatric cancer. METHODS: In the current study, we established a medulloblastoma transcriptome database of 460 samples retrieved from three published datasets (GSE21140, GSE37382, and GSE37418). With this database, we identified a 23-gene signature that is significantly associated with the medulloblastoma subgroups and achieved a classification accuracy of 95.2%. RESULTS: The 23-gene signature was further validated in a long-term cohort of 142 Chinese medulloblastoma patients. The 23-gene signature classified 21 patients as WNT (15%), 41 as SHH (29%), 16 as Group 3 (11%), and 64 as Group 4 (45%). For patients of WNT, SHH, Group 3, and Group 4, 5-year overall-survival rate reached 80%, 62%, 27%, and 47%, respectively (p < 0.0001), meanwhile 5-year progression-free survival reached 80%, 52%, 27%, and 45%, respectively (p < 0.0001). Besides, SHH/TP53-mutant tumors were associated with worse prognosis compared with SHH/TP53 wild-type tumors and other subgroups. We demonstrated that subgroup assignments by the 23-gene signature and Northcott's NanoString assay were highly comparable with a concordance rate of 96.4%. CONCLUSIONS: In conclusion, we present a novel gene signature that is capable of accurately and reliably assigning FFPE medulloblastoma samples to their molecular subgroup, which may serve as an auxiliary tool for medulloblastoma subtyping in the clinic. Future incorporation of this gene signature into prospective clinical trials is warranted to further evaluate its clinical.
引用
- Wang Y, Huang J, Yin X, et al. Development and validation of a 23-gene expression signature for molecular subtyping of medulloblastoma in a long-term Chinese cohort. Acta Neurochir (Wien). 2024. PMID: 38329556. doi:10.1007/s00701-024-05922-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。